A novel activating, germline JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis

Impact of isolated germline JAK2V617I mutation on human hematopoiesis

(2013) A. J. Mead et al.   BLOOD

JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone

(2012) A. L. Godfrey et al.   BLOOD

Heterodimeric JAK–STAT activation as a mechanism of persistence to JAK2 inhibitor therapy

(2012) Priya Koppikar et al.   NATURE

Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F

(2012) Rajintha M Bandaranayake et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

ICD Leads and Postmarketing Surveillance

(2012) Mark D. Carlson   NEW ENGLAND JOURNAL OF MEDICINE

MPL Mutation Profile in JAK2 Mutation-negative Patients With Myeloproliferative Disorders

(2011) Wanlong Ma et al.   DIAGNOSTIC MOLECULAR PATHOLOGY

Phosphorylation of p27Kip1 by JAK2 directly links cytokine receptor signaling to cell cycle control

(2011) H Jäkel et al.   ONCOGENE

Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms

(2010) F. X. Schaub et al.   BLOOD

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

(2010) A. Quintas-Cardama et al.   BLOOD

JAK2V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms

(2010) Stephen T Oh et al.   Expert Review of Hematology

p27 deregulation by Skp2 overexpression induced by the JAK2V617 mutation

(2009) A. Furuhata et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis

(2009) L. Teofili et al.   HAEMATOLOGICA

A JAK2 Interdomain Linker Relays Epo Receptor Engagement Signals to Kinase Activation

(2009) Lequn Zhao et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Acquired mutations in TET2 are common in myelodysplastic syndromes

(2009) Saskia M C Langemeijer et al.   NATURE GENETICS

Mutation inTET2in Myeloid Cancers

(2009) François Delhommeau et al.   NEW ENGLAND JOURNAL OF MEDICINE

SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling

(2009) S Haan et al.   ONCOGENE

KIT and Mastocytosis

(2008) Ken-Hong Lim et al.   ACTA HAEMATOLOGICA

Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease

(2008) A. Agarwal et al.   BLOOD

YRRL motifs in the cytoplasmic domain of the thrombopoietin receptor regulate receptor internalization and degradation

(2008) I. S. Hitchcock et al.   BLOOD

Mutation Profile of JAK2 Transcripts in Patients with Chronic Myeloproliferative Neoplasias

(2008) Wanlong Ma et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice

(2007) R. Tiedt et al.   BLOOD